Abzena, the leading end-to-end integrated CDMO for Antibody Drug Conjugates (ADCs) and complex biologic molecules, has strengthened its senior leadership team with the appointment of Joe Principe as Chief Commercial Officer, and Matthew Pinkston as Vice President, Program Management.
Having worked in the CDMO industry for over 25 years, Joe Principe joins Abzena to strengthen commercial activities, establish a best-in-class experience for Abzena clients, and drive further commercial growth for the company.
Commenting on his appointment, Joe said: “I believe in the technologies and capabilities of Abzena and the company’s vision and values. Abzena is on the cutting edge of pharmaceutical science and this is an exciting opportunity for me to help drive the company into its next phase of growth.
Matthew Pinkston joins Abzena as Vice President of Program Management with over 13 years of combined consulting and industry experience across the life sciences space. Matthew’s deep experience in areas including operations strategy, manufacturing optimization and R&D management, will drive the operational focus and excellence of Abzena forward for the next phase of growth.
Matthew said: “Abzena’s key focus is on being a patient and customer-first organization, combining this with a high degree of collaboration that is driven by strong technical capabilities is a combination that other CDMOs cannot offer. I am looking forward to supporting Abzena through an exciting period of growth”.
Both appointments support Abzena’s commitment to helping its customers achieve their scientific and commercial goals by providing cutting edge science and solutions.
Matthew Stober, CEO of Abzena said: “Joe and Matthew joining the senior leadership team is a strong addition supporting the objectives of the company as we move forward. Both have extensive industry experience which, when partnered with their ability to bring added focus to the team’s activities, provides a real benefit to Abzena and the clients we serve”.
“These appointments are part of the continued focused growth of the organization to ensure that we are continuing to deliver the best service to our customers through our market leading bioconjugation and biologics technologies.”
